BioNeutra Global Corporation
BGA.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.24M | 1.94M | 1.82M | 1.99M | 1.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.24M | 1.94M | 1.82M | 1.99M | 1.89M |
| Cost of Revenue | 1.62M | 1.34M | 1.44M | 167.50K | 1.22M |
| Gross Profit | 616.50K | 599.20K | 384.60K | 1.82M | 665.30K |
| SG&A Expenses | 764.30K | 1.21M | 804.40K | 1.00M | 848.10K |
| Depreciation & Amortization | 39.60K | 31.80K | 41.00K | 41.70K | 42.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.44M | 2.60M | 2.31M | 1.23M | 2.15M |
| Operating Income | -204.90K | -659.00K | -485.60K | 756.50K | -261.40K |
| Income Before Tax | -302.20K | -553.30K | -617.50K | 1.02M | -995.80K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -302.20K | -553.30K | -617.50K | 1.02M | -995.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -302.20K | -553.30K | -617.50K | 1.02M | -995.80K |
| EBIT | -204.90K | -659.00K | -485.60K | 756.50K | -261.40K |
| EBITDA | -167.60K | -506.20K | -321.70K | 980.20K | -56.30K |
| EPS Basic | -0.01 | -0.01 | -0.01 | 0.02 | -0.02 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | 0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | 0.02 | -0.02 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | 0.01 | -0.01 |
| Average Basic Shares Outstanding | 46.45M | 46.45M | 46.45M | 45.70M | 46.45M |
| Average Diluted Shares Outstanding | 46.45M | 46.45M | 46.45M | 45.70M | 46.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
